This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Pernix Therapeutics Holdings, Inc.
Drug Names(s): Trexima; sumatriptan and naproxen (MT 400)
Description: Trexima is a combination of sumatriptan (5-HT1B/1D agonist) and naproxen sodium in a single tablet. Sumatriptan tablets are approved for the acute treatment of migraines with or without aura in adults. Naproxen sodium is an approved non-steroidal anti-inflammatory drug (NSAID).
POZEN and GSK
In June 2003, POZEN and GlaxoSmithKline (GSK) announced that they signed an agreement for the development and commercialization of proprietary combinations of a triptan and a long-acting non-steroidal anti-inflammatory drug (NSAID). The combinations covered by the agreement are among the combinations that POZEN referred to as MT 400 technology. POZEN had the right to receive $25 million in initial payments by GSK.
Under the agreement, POZEN is responsible for the pre-clinical, clinical, and regulatory development activities for Trexima, while GSK is responsible for formulation development, manufacturing and commercialization.
In November 2011, POZEN announced that it sold most of the future royalty and milestone payments under its collaboration and license agreement with GlaxoSmithKline covering Treximet (sumatriptan/naproxen sodium) sales in the United States to a financial investor for $75 million.
By virtue of the agreement, the financial investor...See full deal structure in Biomedtracker
Partners: Aralez Pharmaceuticals Inc.
Additional information available to subscribers only: